Pfizer comes out all guns blazing to protect Lipitor beyond LOE
This article was originally published in Scrip
Executive Summary
As Pfizer enters the final countdown towards Lipitor's loss of US market exclusivity, the company is talking bullishly about the prospects for its best-selling brand, at least until mid-way through next year. Executives elaborated on a number of tactics they are implementing to retain patients.